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Patients	with	infectious	mononucleosis	(IM)	undergoing	primary	EBV	infection	show	large	expansions	of	
EBV-specific	CD8+	T	cells	in	the	blood.	While	latent	infection	of	the	B	cell	pool	is	quickly	controlled,	virus	
shedding	from	lytically	infected	cells	in	the	oropharynx	remains	high	for	several	months.	We	therefore	studied	
how	responses	localize	to	the	tonsil,	a	major	target	site	for	EBV,	during	primary	infection	and	persistence.	In	
acute	IM,	EBV-specific	effectors	were	poorly	represented	among	CD8+	T	cells	in	tonsil	compared	with	blood,	
coincident	with	absence	of	the	CCR7	lymphoid	homing	marker	on	these	highly	activated	cells.	In	patients	who	
had	recently	recovered	from	IM,	latent	epitope	reactivities	were	quicker	than	lytic	reactivities	both	to	acquire	
CCR7	and	to	accumulate	in	the	tonsil,	with	some	of	these	cells	now	expressing	the	CD103	integrin,	which	
mediates	retention	at	mucosal	sites.	By	contrast,	in	long-term	virus	carriers	in	whom	both	lytic	and	latent	
infections	had	been	controlled,	there	was	2-	to	5-fold	enrichment	of	lytic	epitope	reactivities	and	10-	to	20-fold	
enrichment	of	latent	epitope	reactivities	in	tonsil	compared	with	blood;	up	to	20%	of	tonsillar	CD8+	T	cells	
were	EBV	specific,	and	many	now	expressed	CD103.	We	suggest	that	efficient	control	of	EBV	infection	requires	
appropriate	CD8+	T	cell	homing	to	oropharyngeal	sites.
Introduction
EBV, a γ1-herpesvirus widespread in the human population, is the 
causative agent of infectious mononucleosis (IM), a self-limiting 
lymphoproliferative disease, and is etiologically linked to a number 
of lymphoid and epithelial malignancies (reviewed in ref. 1). Pri-
mary infection occurs by the oral route and, at least as witnessed 
in IM patients, is characterized by extensive replication of the virus 
in permissive cells, probably mucosal epithelial cells closely associ-
ated with pharyngeal lymphoid tissues (2); this leads to the release 
of high titers of infectious virus into the throat. At the same time, 
the virus initiates latent growth-transforming infections within 
the B cell pool, best visualized in tonsils from IM patients, where 
immunohistochemical staining has revealed large numbers of latent 
antigen-positive B lymphoblasts in extrafollicular areas of the tis-
sue (3, 4). This virus-driven expansion generalizes the infection and 
establishes a lifelong reservoir of latently infected memory B cells 
that preferentially populate the mucosal lymphoid tissues of the 
Waldeyer ring (5, 6). The majority of these infected cells have by then 
returned to the resting state and have downregulated expression of 
most if not all EBV latent cycle proteins. However their occasional 
reactivation into the productive (lytic) cycle is thought to reseed foci 
of virus replication at oropharyngeal mucosal sites, which explains 
why many asymptomatic virus carriers continue to shed low levels 
of infectious virus detectable in throat washings; furthermore, virus 
produced at these sites is thought also to initiate new growth-trans-
forming infections in locally infiltrating B cells (7).
These events appear to be controlled in part by immune T cell sur-
veillance. Thus, primary infection as seen in IM patients is associat-
ed with a large expansion of CD8+ T cell numbers in the blood, and 
recent work has shown that many of these activated CD8+ T cells 
are EBV specific. The most abundant responses have been mapped 
by HLA class I tetramer staining to particular viral epitope peptides 
derived from proteins of the EBV lytic cycle, with smaller responses 
directed against latent protein epitopes (8, 9). As the infection sub-
sides, these epitope-specific CD8+ T cell populations in the blood 
fall to lower numbers and switch from the original phenotype of 
activated effector cells (expressing the activation marker CD38 and 
lacking central memory markers such as CCR7) to a resting CD38-
negative phenotype. We and others (9–12) have found that lytic and 
latent epitope responses not only show different kinetics of expan-
sion and contraction over the course of primary infection but also, 
with resolution of symptoms, rapidly acquire somewhat different 
memory cell phenotypes. These differences are also apparent in 
memory populations in the blood of long-term virus carriers. Thus, 
the lytic epitope–specific population tends to retain more cells in 
the CCR7-effector memory compartment (with some of these cells 
switching from CD45RO to CD45RA expression) and have fewer 
cells entering the CD45RO+CCR7+ central memory pool.
Correlating these detailed parameters of the immunological 
response with coincident virological events is difficult because, 
as in most studies of virus infection in humans, all available 
Nonstandard	abbreviations	used: CLA, cutaneous lymphocyte-associated antigen; 
EBNA, EBV nuclear antigen; ELISpot, enzyme-linked immunospot; IM, infectious 
mononucleosis; SFC, spot-forming cell.
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immunological readings come exclusively from peripheral blood 
and not from the principal anatomical site of virus infection. The 
limitations of assays solely on blood are best illustrated by recent 
studies of herpes simplex virus (HSV), an agent that typically rep-
licates in skin epidermis. These show that HSV-specific CD8+ T 
cells are low in peripheral blood but highly enriched within the 
CD8+ T cell subset expressing the 
cutaneous lymphocyte-associat-
ed antigen (CLA) and selectively 
homing to the skin (13, 14). 
 The issue of T cell homing is 
particularly germane to EBV 
infection, wherein virus repli-
cation and also latent infection 
preferentially involve cells in the 
Waldeyer ring. Little is known 
about immune controls at this 
location. However, we suspected 
that such controls may be sub-
optimal in acute IM because IM 
patients have large numbers of 
lytic epitope–specific CD8+ T 
cells in the blood, yet viral shed-
ding in the throat reportedly 
remains high for several months, 
long after the resolution of dis-
ease symptoms (15). Here we 
compare CD8+ T cell responses 
to EBV in the blood with those 
seen at 1 of the major oropha-
ryngeal sites of infection, the 
tonsil, in paired samples from 3 
different types of donor: acute 
IM patients, recently recovered 
post-IM patients, and long-
term carriers. In all 3 cases, the 
situation in tonsil is different 
from that in the blood, and in 
each case, the tonsillar picture 
provides a much more informed 
view of the virus-host balance.
Results
Evolution of viral loads in the oropharynx and PBMCs after acute IM. In 
an initial series of experiments, we monitored levels of EBV infec-
tion in the oropharynx and in the circulating B cell reservoir dur-
ing and after acute primary infection. Throat washing and periph-
eral blood samples were taken from the time of acute IM through 
Figure 1
EBV genome load quantitation in IM patients, post-
IM patients, and long-term carriers. (A) EBV genome 
copies in 1 ml of concentrated throat washing (upper 
panel) and 106 PBMCs (lower panel) from an IM patient 
(IM-171) from whom samples were taken during acute 
disease (days 0–14) and at intervals up to 4 months 
later. Upper limits of genome levels in throat washing 
and blood samples from healthy carriers are indicated 
by the dashed lines. (B) EBV genome copies were 
estimated in 106 tonsillar cells (upper panels) or 106 
PBMCs (lower panels) from tonsillectomy patients who 
were either undergoing acute IM or recently recovered 
from IM (post-IM) or were long-term carriers.
Figure 2
Frequency of EBV-specific CD8+ T cells in PBMCs and matched tonsil preparations from IM, post-IM, 
and long-term carrier tonsillectomy patients. (A) PBMCs (left panels) and tonsillar cells (right panels) from 
acute IM patient IM-5 were stained with either HLA-B*0801 tetramers containing the lytic cycle epitope 
RAK or latent cycle epitope QAK peptides or the HLA-A*0201 tetramer containing the lytic cycle epitope 
YVL peptide and subsequently stained with anti-CD8 mAbs. Values shown refer to the percentage of 
CD8+ T cells that stained with the tetramer. (B) PBMCs and tonsillar cells from post-IM-1 were stained as 
described above with HLA-A*0201 tetramers containing either the lytic cycle epitope YVL or GLC or the 
latent cycle epitope CLG peptides. (C) PBMCs and tonsillar cells from carrier-32 were stained as described 
above with the HLA-B*0801 tetramers containing the lytic cycle epitope RAK or latent cycle epitope FLR 
peptides or the HLA-A*0201 tetramer containing the lytic cycle epitope GLC peptide.
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convalescence	and at intervals over a further 4–6 months. Figure 1A 
illustrates the data from a representative patient, IM-171; 
EBV DNA loads were determined by quantitative PCR assay in 
a standard volume (1 ml) of the throat washing sample and in a 
standard number (106) of PBMCs. The high viral loads detected 
in PBMCs during acute disease fell substantially during the next 
2 weeks to a value that lay toward the top end of the normal range 
shown by healthy virus carriers and were subsequently maintained 
at this level. By contrast, the high viral loads present in throat 
washings during acute disease showed no significant reduction 
over the entire course of study, always remaining well above the 
normal range of virus shedding shown by healthy carriers. These 
results are in accord with a recent detailed study showing that high 
oropharyngeal levels of virus shedding are maintained for many 
months following IM, long after resolution of symptoms and the 
concomitant fall in latently infected B cell load in the blood (15).
The main body of experiments in the present work analyzed 
matching tonsil and blood mononuclear cell samples from 6 
patients tonsillectomized during acute IM, 2 patients tonsillec-
tomized at approximately 3 months after IM, and 11 tonsillec-
tomy patients who had no history of EBV-related disease but were 
long-term virus carriers. Figure 1B shows the EBV DNA loads in 
106 tonsillar lymphocytes (upper panels) and 106 PBMCs (lower 
panels) from the 3 groups of patients. The acute IM patients 
showed very high EBV loads at both sites, as expected. The post-
IM patients showed tonsillar EBV loads around 5-fold lower 
than the acute IM values but still 100-fold higher than long-term 
carrier values, while PBMC EBV loads in post-IM patients were 
around 20-fold lower than the acute IM values, at the very top 
of the normal range. By comparison, the long-term virus carriers 
all had low loads both in tonsillar lymphocytes and in PBMCs, 
their mean values being, respectively, about 500-fold and 200-fold 
lower than the mean values in acute IM patients. These virologi-
cal assays confirm that the cell preparations collected for immu-
nological analysis showed levels of EBV infection consistent with 
those expected for the 3 different patient groups.
EBV-specific CD8+ T cell numbers in blood and tonsil with evolution 
of the infection. We next monitored the EBV-specific CD8+ T cell 
numbers in the same blood and tonsillar preparations by stain-
ing with HLA class I tetrameric complexes specific for EBV lytic 
or latent epitopes; this was followed by anti-CD8 mAb staining 
and flow cytometric analysis.
Matching PBMCs and tonsil preparations from 6 acute IM 
patients were studied. In each case, as already described in an ear-
lier work (9), HLA class I tetramer staining of the PBMCs showed 
high levels of EBV-specific T cells in this compartment. Howev-
er, these cells were always represented to a much lesser extent in 
tonsillar CD8+ populations. Results for 1 representative patient, 
IM-5 (positive for HLA-B*0801 and HLA-A*0201) are shown 
in Figure 2A. In the blood, responses to the immunodominant 
HLA-B*0801–restricted RAK and HLA-A*0201–restricted YVL 
lytic cycle epitopes constituted, respectively, 46.71% and 3.29% 
of the CD8+ T cells in PBMCs, with cells specific for the HLA-
B*0801–restricted latent cycle QAK epitope constituting 2.16% of 
the CD8+ population. When tonsillar cells from the same patient 
were analyzed in parallel, responses to all 3 epitopes were signifi-
cantly lower than those in blood (Figure 2A, right column). Thus, 
RAK and YVL responses in the CD8+ T cell pool were reduced 3- to 
4-fold to 13.13% and 1.09%, respectively, while the latent epitope 
response was reduced less markedly, to 1.6%. The relative paucity 
of EBV-specific cells in the tonsil compared with blood of IM-5 
was also apparent when the cells were tested in overnight enzyme-
linked immunospot (ELISpot) assays of epitope peptide–induced 
IFN-γ release and results expressed as number of IFN-γ spot-form-
ing cells (SFCs) per 105 CD8+ T cells (Supplemental Table 1; sup-
plemental material available online with this article; doi:10.1172/
JCI24810DS1). Note that this functional assay is useful for com-
paring relative numbers of responsive cells in the 2 populations, 
but in each case likely underestimates the true frequency of such 
cells because activated primary effectors are highly prone to apop-
tosis in vitro. Tetramer analysis of samples from an additional 5 
acute IM patients confirmed low levels of lytic and latent epitope 
responses in tonsil compared with blood (see Figure 3).
Figure 3
Summary of the frequency of EBV-specific responses in the PBMCs 
and tonsils of 6 IM, 2 post-IM, and 11 long-term carrier tonsillectomy 
patients; symbols connected by a line refer to a particular epitope-spe-
cific response in an individual donor. (A) Percentage of CD8+ T cells 
staining with EBV lytic epitope–specific tetramers in IM (left panel) and 
post-IM (middle panel) patients and long-term carriers (right panel). (B) 
Percentage of CD8+ T cells staining with EBV latent epitope–specific 
tetramers in IM (left panel) and post-IM (middle panel) patients and 
long-term carriers (right panel). P values shown were obtained using 
linear mixed model analysis as described in Methods. Significant differ-
ences are indicated by an asterisk. In addition, in acute IM, the reduc-
tion in epitope-specific T cell representation in tonsil relative to blood 
was significantly greater for lytic than for latent reactivities (P = 0.004); 
also, in carriers, the increase in epitope-specific T cell representation 
in tonsil relative to blood was significantly greater for latent than for lytic 
epitopes (P = 0.003).
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We next examined EBV-specific responses in 2 patients who 
underwent tonsillectomy 3 months following IM. They showed 
a consistent pattern of results, which was distinct from that seen 
in patients with acute disease. Data from 1 of these patients, the 
HLA-A*0201–positive individual post-IM-1 are shown in Figure 
2B. In this case, PBMCs and tonsillar preparations were stained 
using the HLA-A*0201 tetramers refolded with the YVL and GLC 
lytic epitope peptides and with the CLG latent epitope peptide. 
In the blood, the lytic epitope–specific T cells constituted 2.03% 
and 1.75% of the CD8 population, respectively; such values are 
typical of those of an earlier study in which the blood of HLA-
A*0201–positive patients was analyzed in the months following 
IM (9). Once again, as in acute IM, representation of these same 
responses in tonsillar CD8+ T cells was reduced, in this case by 
4- to 7-fold. In contrast, the response to the latent CLG epitope, 
usually regarded as a subdominant response on the basis of its 
frequency in PBMCs, was detected at a typically low level (0.13%) 
among CD8+ T cells in the blood but was enriched approximately 
4-fold in the tonsil. These different patterns were also apparent 
when post-IM PBMC and tonsillar preparations were screened in 
IFN-γ ELISpot assays for functional responses to epitope peptide 
stimulation. Representative results from post-IM-1 are shown in 
Supplemental Table 1. The response to the YVL lytic epitope was 
represented at a low level in tonsil compared with blood, where-
as responses both to CLG and to a stronger latent epitope for 
which tetramers were not available, the HLA-B*4402–restricted 
EEN epitope from the EBV nuclear antigen 3C (EBNA3C), were 
clearly amplified in the tonsil.
These findings showed that EBV-specific T cells were differen-
tially distributed between blood and tonsil and implied that their 
relative distribution between these 2 sites may change over time. 
To further explore this idea, we next examined blood and tonsil 
samples from 11 long-term EBV carriers in whom both lytic and 
latent infections had been brought under control. In these donors, 
levels of EBV epitope–specific T cells in the blood were typical of 
those seen in earlier studies of healthy carriers (9, 16). However, 
all such reactivities were found to be significantly enriched in the 
matching tonsil specimens. Figure 2C shows FACS plots of a rep-
resentative HLA-A*0201, B*0801–positive donor, carrier-32. Tet-
ramer staining identified 1.67% and 0.11% of CD8+ T cells in the 
blood as specific for the HLA-B*0801/RAK and HLA-A*0201/GLC 
lytic epitopes, respectively, and 0.24% as specific for the latent cycle 
HLA-B*0801/FLR epitope. In the tonsil, these percentages were 
increased dramatically, by 5-fold for the 2 lytic cycle epitopes and 
by 11-fold for the latent cycle epitope. Collectively, therefore, these 
3 responses accounted for almost 12% of tonsillar CD8+ cells in this 
long-term carrier. Again, we were able to confirm the enrichment 
of EBV-specific T cells in tonsillar tissue using the ELISpot assay 
of IFN-γ release as a functional readout. Representative results 
from the HLA-A*0201–positive carrier-25 and the HLA-B*0801–
positive carrier-27 are shown in Supplemental Table 1. Carrier-25 
responses to the lytic YVL and latent CLG epitopes were enriched 
in tonsillar CD8 populations by 6-fold and more than 40-fold, 
respectively; carrier-27 responses to the lytic RAK and latent FLR 
epitopes were enriched by 11-fold and 28-fold, respectively.
The results of tetramer staining analysis from all 3 donor groups 
are summarized in Figure 3. These reflect the cumulative data for 
responses to 5 lytic epitopes (Figure 3A) and 5 latent epitopes 
(Figure 3B), in each case restricted through 1 of 3 different HLA 
class I alleles. Each donor group showed its own specific pattern of 
results. In results consistent with and extending those of a previ-
ous study (17), acute IM patients showed very strong representa-
tion of lytic and to a lesser extent latent epitope responses in the 
blood, while these responses were decreased in the tonsil by 3- to 
4-fold for the lytic reactivities and to a lesser extent for the latent 
reactivities. The post-IM patients showed lower levels of EBV 
lytic reactivities in the blood, but, again, all 6 responses analyzed 
were reduced by 3- to 8-fold in the tonsil; yet in the same post-
IM patients, the 2 latent epitope–specific responses we were able 
to study both showed enrichment in tonsillar CD8 populations. 
In the long-term carrier group, the situation was different again. 
Here both sets of responses were enriched in tonsil compared with 
blood, by a factor of 2- to 4-fold for lytic epitope reactivities and 
10- to 20-fold for latent reactivities.
Comparison of EBV-specific and CMV-specific CD8+ T cell distributions. 
We reasoned that the accumulation of EBV-specific CD8+ T cells in 
the tonsils of long-term carriers might reflect a trend common to all 
responses induced by persistent viruses. To check this, we studied 
particular donors who were persistently infected with both EBV and 
with CMV, a β-herpesvirus that is carried as a more generalized infec-
tion of myeloid and other cell types. Figure 4 shows the results from 
1 such dually infected donor, the HLA-A*0101, B*0801–positive 
Figure 4
Representation of EBV- and CMV-specific 
CD8+ T cells in PBMCs and tonsil of a long-
term EBV/CMV carrier. PBMCs (left pan-
els) and tonsillar cells (right panels) were 
stained as before. (A) Cells were stained 
with HLA-B*0801 tetramers containing the 
EBV lytic epitope RAK and latent epitope 
FLR peptides. (B) Cells were stained with 
HLA-A*0101 tetramers containing the CMV 
peptides VTE and YSE. Results are pre-
sented as in Figure 2.
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carrier-26. Memory T cell responses to the HLA-B*0801–restricted 
EBV lytic (RAK) and latent (FLR) epitopes were enriched in ton-
sil compared with blood by factors of 3- and 10-fold, respectively. 
Indeed, a second HLA-B*0801 latent epitope (QAK) was likewise 
amplified almost 10-fold in tonsil (data not shown), such that col-
lectively these 3 reactivities accounted for 20% of all CD8+ T cells 
in the tonsil. The contrast between this and the distribution of the 
CMV-specific CD8+ T cells was marked. Tetramer staining showed 
that memory CD8+ T cells specific for 2 HLA-A*0101–restricted 
CMV epitopes, the pp50-derived VTE and pp65-derived YSE, were 
well represented among CD8+ T cells in the blood, but were 3- to 
10-fold less frequent among tonsillar CD8+ T cells.
Phenotype of EBV-specific CD8+ T cells in blood and tonsil with evolution 
of the infection. Having mapped the distribution of EBV-specific T 
cells between blood and tonsil in individuals at 3 different stages 
of EBV infection, we now sought to determine the phenotype of 
these T cells in terms of markers of effector function, differentia-
tion, and migratory capacity. These included CD38, a marker of 
activated effector cells (8); CD45RO, a CD45 isoform expressed 
by both activated cells and antigen-experienced memory cells 
(18); and CD45RA, an isoform historically associated with naive 
T cells but now also shown to be reexpressed on some antigen-
experienced cells (19). Expression of the 2 isoforms was inversely 
related throughout, so data are only shown for CD45RO. We also 
stained for the costimulatory molecules CD27 and CD28 (20, 21), 
whose downregulation is thought to be associated with terminal 
differentiation (22), and for a range of migratory markers. These 
included CCR7 and CD62-l, whose expression identifies central 
memory cells with the ability to migrate to lymphoid tissues (23); 
CCR9 and α4β7, both characteristic of cells migrating to gut-
associated lymphoid tissue (24, 25); CCR4 and CLA, which are 
characteristic of cells migrating to the skin (26, 27); CCR10, a che-
mokine receptor whose ligands are expressed by a diverse range of 
epithelial cells (28, 29); and CD103, an integrin characteristic of 
cells retained at mucosal epithelial sites (30).
Preparations from PBMCs and tonsil were stained with EBV-
specific tetramers, followed by mAbs specific for CD8 and the 
relevant surface marker. Figure 5 illustrates typical phenotype 
data obtained from acute IM patients, in this case from the HLA-
B*0801–positive patient IM-5. Whether in blood or tonsil, cells 
specific for the immunodominant RAK lytic epitope showed a 
highly activated phenotype, expressing CD38 and CD45RO in 
the absence of CD45RA. As previously described (17), CD27 and 
CD28 were downregulated in a significant fraction of these EBV-
specific cells in the blood, although such downregulation was 
less apparent in the tonsil (data not shown). These activated cells 
were largely devoid of homing markers, in particular the lym-
phoid homing markers CCR7 and CD62-l, and also lacked the 
CD103 marker of epithelial retention. These findings were typi-
cal not only of the large lytic epitope–specific populations but 
also of the generally smaller populations of latent epitope–spe-
cific cells seen in IM (data not shown).
A different picture was observed when we studied EBV-specific 
reactivities in the blood and tonsil of 2 post-IM patients, both 
3 months after disease resolution. Figure 6 shows representa-
tive data from 1 of these patients, the HLA-A*0201–positive 
post-IM-1. By this time, most lytic (YVL; Figure 6A) and latent 
(CLG; Figure 6B) epitope-specific cells in the blood had lost CD38 
expression, but interestingly, in the tonsil, 45–50% of these same 
epitope-specific populations remained CD38 positive, which sug-
gests their continued antigen-driven activation. In terms of CD45 
isoform status, EBV lytic epitope–specific cells in the blood were 
heterogeneous for expression of these isoforms, with more than 
half now losing CD45RO and gaining CD45RA, whereas all latent 
epitope–specific cells remained CD45RO positive; these differ-
ences are in accord with our earlier findings on blood samples 
from post-IM patients (9). In the tonsil, however, we found that 
both lytic and latent reactivities remained CD45RO positive. Dif-
ferences were also observed in the lymphoid migration markers 
on lytic versus latent epitope reactivities in post-IM blood; CCR7 
(and CD62-l; data not shown) were essentially absent from the 
Figure 5
Analysis of EBV-specific CD8+ T cells from an acute IM patient for 
CD38, CD45RO, CCR7, and CD103 status. PBMCs (left panels) or 
tonsillar cells (right panels) from IM-5 were stained with the HLA-
B*0801 tetramer containing the lytic epitope RAK peptide, followed 
by mAbs specific for CD8 and the relevant marker. Flow cytometric 
analysis was performed after gating on CD8+ cells, and profiles show 
tetramer staining versus the third marker (CD38, CD45RO, CCR7, and 
CD103). Values shown refer to the percentage of tetramer-positive 
cells that express the relevant marker.
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lytic epitope population, whereas more than 50% of latent epit-
ope–specific cells had reacquired both markers by this time. These 
differences were coincident with the increased representation of 
latent but not lytic epitope responses in the tonsil. Most impor-
tant were the findings from CD103 staining. While very few if any 
EBV-specific T cells in the blood expressed this marker, in the ton-
sil, around 28% of the lytic epitope population and 57% of latent 
epitope population were clearly CD103 positive, which implied 
active retention of these populations at this site.
Analysis of paired samples from long-term virus carriers also 
gave a consistent pattern of results, here illustrated with respect 
to lytic (RAK; Figure 7A) and latent (FLR; Figure 7B) epitope 
responses in the HLA-B*0801–positive carrier-32. At this stage 
of infection, few lytic or latent epitope–specific cells express 
the CD38 activation marker, whether in the blood or the tonsil. 
This is consistent with the very low viral loads present at both 
of these sites (see Figure 1B). Differences in CD45 isoform sta-
tus between lytic and latent epitope–specific populations in the 
blood were now less marked than those in post-IM patients, 
with both specificities expressing predominantly CD45RO, 
and again all tonsillar populations 
were CD45RO+CD45RA–. Both sets of 
epitope-specific memory cells in the 
blood were consistently negative for 
markers of migration to gut-associ-
ated lymphoid tissue (CCR9, α4β7) 
or skin (CCR4, CLA) (data not shown) 
but did contain some cells with lym-
phoid homing markers. Acquisition of 
CCR7 (and CD62-l; data not shown) 
by EBV-specific cells in the blood was 
relatively low in this particular patient 
but still illustrated the consistent 
trend for greater movement of the 
latent reactivities to a CCR7-positive 
central memory phenotype. Finally, 
both lytic and latent reactivities were 
again CD103 negative in the blood, 
but a significant proportion of these 
cells expressed CD103 in the tonsil.
The essential trends in phenotype 
change are illustrated in Figure 8, 
which compiles the data from all sub-
jects: 6 acute IM patients, 2 post-IM 
patients, and 11 long-term carriers. 
Results are expressed as the percent-
age of tetramer-positive cells that 
were also positive for the marker in 
question, CD38, CD45RO, CCR7, 
or CD103. In each case, individual 
symbols represent 1 epitope-specific 
response, with lytic epitopes indicated 
by filled and latent epitopes by open 
symbols. The CD38 activation mark-
er was highly expressed on all cells in 
acute IM, whether in blood or tonsil. 
Within 3 months after IM, CD38 had 
been lost from most EBV-specific 
cells in the blood but was retained on 
about 50% of such cells in the tonsil. 
By contrast, in long-term carriers, most cells at both sites no 
longer expressed this activation marker. The CD45RO isoform 
was highly expressed on acute IM cells in both compartments 
but, immediately after IM, many lytic epitope specificities in the 
blood had reverted to a CD45RA+CD45RO– phenotype, whereas 
in the tonsil, they remained CD45RO+ throughout. Figure 8 
illustrates important differences in the CCR7 status of lytic ver-
sus latent specificities in the blood; a second lymphoid homing 
marker, CD62-l, showed a very similar pattern (data not shown). 
While the activated cells in acute IM were all CCR7 negative, 
the subsequent acquisition of lymphoid homing potential was 
more marked among latent than among lytic reactivities, both 
in post-IM patients and in long-term carriers. These trends were 
generally not as apparent in the tonsil, where, following entry, 
the CCR7 and CD62-1 markers appear to have been downreg-
ulated in most cells. Finally, as expected, the CD103 marker 
of retention at mucosal sites was absent from the blood at all 
time points; in the tonsil however, while acute IM effectors lack 
CD103, the marker was progressively acquired as these cells 
accumulated at the site of infection.
Figure 6
Analysis of EBV-specific CD8+ T cells from a patient recently recovered from acute IM for CD38, 
CD45RO, CCR7, and CD103 status. PBMCs (left panels) or tonsillar cells (right panels) from post-
IM-1 were stained with HLA-A*0201 tetramers containing either the lytic cycle epitope YVL peptide 
(A) or the latent cycle epitope CLG peptide (B), as well as with antibodies specific for CD38, 
CD45RO, CCR7, and CD103. Flow cytometric analysis was performed after gating on CD8+ cells, 
and profiles are presented as in Figure 5.
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Discussion
This study was prompted by the observation (Figure 1A and ref. 15) 
that EBV replication in the oropharynx remains high for some 
months following IM despite the large numbers of EBV lytic epi-
tope–specific CD8+ T cells in the blood during the acute disease. 
Accordingly, we found that these lytic epitope reactivities were 
much lower (by a factor of 3- to 4-fold) in tonsillar CD8 popula-
tions than in blood. This lack of obvious recruitment of primary 
effectors to the main sites of infection in oropharyngeal lymphoid 
tissues may be a consequence of the cells’ altered homing phe-
notype. Thus, these activated CD38+ cells have lost expression of 
the CCR7 and CD62-l markers that normally allow entry from 
peripheral blood into lymphoid tissues through high endothelial 
venules. Lymphocyte activation is known to be associated with 
CCR7 loss and the rapid shedding of CD62-l from the cell sur-
face (23, 31). The fact that activated T cells have been observed 
infiltrating many body tissues in IM patients (32) highlights the 
nondirected nature of much of this highly expanded primary T 
cell response. Since EBV replication and shedding into the oro-
pharynx is thought to involve either 
mucosal epithelium or mucosa-associ-
ated B cells as the main permissive cell 
type (1, 2), we were further interested in 
examining EBV-specific T cell popula-
tions for CD103 (αEβ7) expression. This 
integrin is induced by the epithelium-
derived cytokine TGF-β and facilitates 
T cell–epithelial interaction through 
binding of the epithelial cell–specific 
surface adhesion molecule E-cadherin 
(30, 33); CD103 is therefore considered a 
marker of retention at mucosal epithelial 
sites rather than a homing molecule per 
se (34). The fact that primary effectors 
within IM tonsils fail to express CD103 
is further circumstantial evidence that 
even those effectors that do happen to 
infiltrate oropharyngeal lymphoid tis-
sues are not engaging the appropriate 
target sites of virus replication.
As our earlier studies have shown, 
CD8+ T cells specific for EBV latent 
cycle epitopes are less abundant in acute 
IM blood (8, 9), and, with the available 
panel of paired samples from acute IM 
patients, comparisons between blood 
and tonsillar responses to latent epit-
opes were more limited. However, there 
appeared to be a more equal distribution 
of latent epitope–specific CD8+ T cells 
between the 2 sites. The contrast between 
lytic and latent epitope responses became 
clearer, however, when we looked at 
samples from 2 patients who had tonsil-
lectomies in the immediate aftermath 
of IM. Like the samples from patients 
with acute disease, these showed under-
representation of lytic epitope responses 
in tonsillar CD8 populations compared 
with blood, whereas both tetramer analy-
sis and ELISpot assays showed that latent epitope responses had 
begun to accumulate in the tonsil by this stage. Since tonsils lack 
afferent lymphatics (35), this accumulation cannot be explained by 
migration back from peripheral (extranodal) sites, but must have 
resulted from active migration from the blood via high endothelial 
venules. This accords with the fact that, following primary infec-
tion, latent epitope–specific memory cells acquire the CCR7 and 
CD62-l lymphoid homing markers more rapidly and in a greater 
proportion of cells than do lytic epitope–specific memory cells 
(Figure 6 and ref. 9); latent epitope responses would therefore 
be expected to have greater access to the tonsil. Among the cells 
that do access this site, a significant fraction of the latent epitope 
response in particular have now begun to express CD103, which 
implies active retention in the tonsil, and many still expressed 
CD38, which indicates ongoing antigen stimulation. The more 
efficient homing of latent epitope responses to oropharyngeal 
tissues could explain why latent infections of the B cell pool are 
more rapidly controlled than are virus replicative lesions. In this 
context, CD8 responses to latent cycle antigens focus heavily on 
Figure 7
Analysis of EBV-specific CD8+ T cells from a long-term carrier for CD38, CD45RO, CCR7, and 
CD103 status. PBMCs (left panels) or tonsillar cells (right panels) from carrier-32 were stained 
with HLA-B*0801 tetramers containing either the lytic cycle epitope RAK peptide (A) or the 
latent cycle epitope FLR (B) as well as with antibodies specific for CD38, CD45RO, CCR7, 
and CD103. Flow cytometric analysis was performed after gating on CD8+ cells, and profiles 
are presented as in Figure 5.
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the EBNA3A, -3B, -3C family of target antigens (36), proteins that 
are only expressed in the context of growth-transforming B cell 
infections (1). Such growth-transformed cells are thought to arise 
from de novo infections initiated by viruses produced at sites of 
virus replication in the mucosa (37). It is therefore to be expected 
that appropriate targeting of such B cell infections would localize 
near mucosal sites and acquire the retention markers induced by 
that cytokine environment.
The corresponding analysis of EBV-specific memory popula-
tions in the blood and tonsils of long-term virus carriers revealed 
a situation that was distinct from those seen in acute IM and in 
post-IM patients, though one to which post-IM patients most 
likely move over time. Now we found a marked accumulation of all 
EBV specificities in the tonsillar CD8 populations, with percent-
age representation being increased compared with levels in blood 
by a factor of 2- to 5-fold for lytic epitopes and 10- to 20-fold for 
latent epitopes. Remarkably, according to tetramer staining, up 
to 20% of all CD8+ T cells in the tonsil of these long-term carriers 
were directed against defined EBV epitope peptides. Functional 
assays of peptide-induced IFN-γ production gave the same pat-
tern of response distribution, though absolute numbers of SFCs 
in ELISpot assays were always lower than the numbers of tetramer-
positive cells. In this context, we have shown that immediate IFN-γ 
production is restricted to a subset of cells in the CCR7-effector 
memory population (10), and indeed, when the size of that sub-
set was calculated for representative responses from carrier-25 
and carrier-27 (Supplemental Table 1), it ranged from 13% to 47% 
of effector memory cells. Interestingly, however, within any one 
epitope response, the effector memory populations in blood and 
tonsil gave roughly similar values.
We believe that the tonsillar accumulation of EBV-specific 
responses seen in our long-term carriers is genuinely representa-
tive of tonsillar tissue in the asymptomatic carrier state and is not 
an artifact of the recurrent tonsillitis that led to surgery. Thus, the 
patients were clinically healthy, and their tonsils were not inflamed 
at the time of removal. Furthermore, EBV loads in the carrier ton-
sils were uniformly very low, far below those seen in acute IM and 
post-IM samples, and there was no evidence from CD38 staining 
of substantial T cell activation. Arguably the presence of such large 
numbers of these cells in oropharyngeal lymphoid tissues can pre-
vent the outgrowth of EBV-transformed foci and can also main-
tain tight control over chronic lytic replication. The efficiency of 
control over latent growth-transforming infection is reflected by 
the fact that transformed cells are never detectable in the recircu-
lating B cell pool of immunocompetent virus carriers and indeed 
are only seen in tonsillar preparations as short-lived transforma-
tion events occurring in B cells recently infected at sites of replica-
tion (7, 37–39). Virus replication is also well controlled, although 
it is interesting that many healthy virus carriers continue to shed 
very low levels of infectious virus into the throat, despite the pres-
ence of this local immune response. This implies that there may be 
an immunologically privileged site in the oropharynx where low-
level replication can still occur. Alternatively, as seen with other 
herpesviruses (40), complete elimination of replication may be 
hampered by immune evasion proteins that recent results suggest 
may be encoded by EBV lytic cycle genes (41, 42).
It will be important to understand further the basis of this 
marked tonsillar accumulation of EBV-reactive T cells. Clearly 
it cannot be ascribed to some nonspecific inflammatory effect 
generally attracting or retaining CD8+ memory cells against a 
range of persistent viruses. Such a nonspecific effect is seen in 
inflamed rheumatoid synovium, for example, where there is an 
accumulation of many irrelevant CD8 specificities, including 
those against viruses such as EBV and CMV (43, 44). By contrast, 
CMV-reactive cells are virtually excluded from tonsillar popula-
tions, even though they are usually more abundant in the blood 
than the corresponding EBV specificities. We believe that one 
factor favoring the access of EBV-specific cells to the tonsil, par-
ticularly EBV latent specificities, is the significant levels of CCR7 
Figure 8
Compilation of results of phenotypic analysis of EBV-specific CD8+ 
T cells in tonsil and PBMCs from acute IM, post-IM, and long-term 
carrier tonsillectomy patients. (A) Percentage of tonsillar EBV-specific 
CD8+ cells expressing the relevant marker. (B) Percentage of PBMC 
EBV-specific CD8+ cells expressing the relevant marker. Left panels 
show results from acute IM patients; middle panels show results from 
post-IM patients; and right panels show results from long-term carri-
ers. Filled symbols represent results from EBV lytic cycle epitopes, 
while open symbols represent results from EBV latent cycle epitopes. 
Statistical analysis of the data was carried out using a model simi-
lar to that described in the legend to Figure 3. CD38 expression was 
significantly related to infection state both in tonsil (P = 0.0003) and 
in blood (P < 0.0001); furthermore, CD38 was significantly higher in 
tonsil than in blood of post-IM patients (P = 0.04). CD103 expression 
was significantly related to infection state in tonsil only (P = 0.05) and 
was elevated in tonsil compared with blood in both post-IM patients 
and long-term carriers (P = 0.008). Significant differences in CCR7 
expression were only seen in long-term carriers in whom CCR7 was 
significantly higher on latent compared with lytic epitope–specific cells 
in blood (P = 0.003).
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and CD62-l expression displayed by these memory populations in 
the blood; in contrast, circulating CMV-specific memory cells are 
almost entirely devoid of these markers (45, 46). However, other 
factors may be equally important in this context. For example, 
recent work in mouse models indicates that T cells receive spe-
cific migratory instructions depending upon the location in 
which the response is primed (47–49). Thus the fact that EBV is 
an agent preferentially infecting the Waldeyer ring (6) may also 
influence the long-term migration of EBV-specific memory. Most 
important, local antigen stimulation could act both to expand 
and then to retain EBV-specific reactivities within the tonsil once 
the cells have trafficked to that site. Despite these influences over 
the behavior of memory cells, the acute primary response to EBV 
infection, at least as seen in IM patients, is not efficiently targeted 
to the main site of virus replication, and this correlates with pro-
longed viral shedding into the oropharynx. By contrast, both lytic 
and latent memory responses do accumulate in oropharyngeal 
sites in long-term virus carriers, and this is associated with effi-
cient control over the resident infection. Monitoring CD8+ T cell 
responses at a relevant tissue site, rather than in blood, therefore 
gives a much more informative view of the EBV-host balance.
Methods
Tonsillar and PBMC preparations. Tonsil specimens and matching heparin-
ized blood samples were obtained from (a) 6 patients who had undergone 
tonsillectomy during acute IM to relieve airway obstruction due to tonsil-
lar inflammation; (b) 2 patients undergoing tonsillectomy 3 months after 
IM; and (c) 11 patients with no history of EBV-related disease who had 
undergone routine tonsillectomy to treat chronic tonsillitis. All patients 
studied were adolescent or young adults and, with the exception of those of 
the acute IM patients, the tonsils were not inflamed at the time of surgery. 
The clinical diagnosis of acute IM was confirmed by heterophile antibody 
positivity. Routine tonsillectomy patients were confirmed as long-term 
EBV carriers showing IgG anti-virus capsid antibody titers in the normal 
range. A standard serological assay for antiviral IgG antibody (CMVscan 
kit; BD Biosciences) was used per the manufacturer’s instructions to iden-
tify donors who were also carriers of CMV infection. The experiments were 
approved by the Ethics Committee of the Faculty of Clinical Medicine 
Mannheim, Ruprecht-Karls University of Heidelberg, and the South Bir-
mingham Health Authority Local Research Ethics Committee. Tonsillec-
tomy specimens were disaggregated to single-cell suspensions by teasing 
apart the tissue and fine mincing. Mononuclear cells were isolated by puri-
fication over a Lymphoprep gradient (Nycomed) per the manufacturer’s 
instructions. PBMCs were isolated in a similar manner from peripheral 
blood specimens taken at the time of tonsillectomy. In both cases, mono-
nuclear cells were aliquoted, cryopreserved, and stored in liquid nitrogen. 
DNA was isolated from an aliquot of the tonsillar cells for HLA typing by 
sequence-specific oligonucleotide PCR analysis.
Flow cytometric analysis of samples. The cryopreserved mononuclear cell prep-
arations were subjected to analysis using HLA class I tetramers, where the 
relevant class I molecule was refolded with β2 microglobulin and the appro-
priate epitope peptide and complexed with streptavidin-phycoerythrin as 
previously described (9). Viral epitopes are identified in the text by the first 
3 letters of the peptide sequence. The EBV epitopes studied were the HLA-
A*0201–restricted peptides YVLDHLIVV, GLCTLVAML, and TLDYKPLSV, 
derived from the lytic antigens BRLF1, BMLF1, and BMRF1, respectively (9, 
43, 50, 51), and CLGGLLTMV, derived from the latent membrane protein 
LMP2 (52); the HLA-B*0801–restricted peptides RAKFKQLL, derived from 
the lytic antigen BZLF1 (53), and FLRGRAYGL and QAKWRLQTL, both 
derived from the latent cycle nuclear antigen EBNA3A (54, 55); and the 
HLA-B*3501–restricted peptides EPLPQGQLTAY, derived from the lytic 
antigen BZLF1 (50), and HPVGEADYFEY and YPLHEQHGM, derived from 
the latent nuclear antigens EBNA1 and EBNA3A, respectively (55, 56). HLA 
class I tetramers containing CMV epitope peptides were also constructed; 
these included the HLA-A*0101–restricted peptides VTEHDTLLY, derived 
from pp50 (57), and YSEHPTFTSQY, derived from pp65 (58). In all cases 
the tetramer-stained cells were subsequently stained with Tricolor-labeled 
anti-CD8 antibodies (CALTAG Laboratories).
Phenotypic analysis involved staining with the above reagents plus a third 
marker. These included FITC-labeled antibodies specific to CD45RA (Beck-
man Coulter), CD45RO (DakoCytomation), CD27 (BD Biosciences), CD28 
(BD Biosciences), CD38 (BD Biosciences), CD62-l (CALTAG Laboratories), 
and CD103 (BD Biosciences). Unconjugated antibodies specific to CCR4 
(BD Biosciences), CCR7 (R&D Systems), CCR9 (R&D Systems), CCR10 
(Abcam Ltd.), CLA (BD Biosciences), and α4β7 (a kind gift from E. Rainger, 
University of Birmingham, Birmingham, United Kingdom) were also used, 
and binding was revealed using FITC-labeled goat anti-mouse or FITC-
labeled goat anti-rat antibodies (SouthernBiotech). In all cases, cells were 
stained with appropriate isotype control antibodies as negative controls.
ELISpot analysis of samples. ELISpot assays were carried out to determine 
epitope peptide–induced IFN-γ responses as described previously (10). 
These assays included the HLA-B*4402–restricted peptide EENLLDFVRF, 
derived from the latent cycle nuclear antigen EBNA3C (59).
Virus genome load analysis. Quantitative PCR analysis was performed to esti-
mate viral genome levels as described previously (60). DNA for genome quan-
titation was extracted from ultraconcentrated throat washings or 1 × 106 
mononuclear cells derived from single-cell preparations of either tonsil or 
PBMCs using a DNeasy tissue kit (QIAGEN).
Statistical analysis. Statistical analysis was conducted using linear mixed 
models to model log-transformed data using SAS/STAT software (version 8.2; 
SAS Institute Inc.). In the mixed models, random donor effects were included 
together with fixed effects for epitope, tissue compartment, and health state 
where applicable. The P values were not adjusted for multiple testing.
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